Carregant...
Progression after Immunotherapy for Fibrolamellar Carcinoma
BACKGROUND: Fibrolamellar carcinoma (FLC) is a rare malignancy of the liver that differs from typical hepatocellular carcinoma (HCC) in several aspects such as the absence of underlying liver disease and occurrence in younger patients. Even though the survival rates in FLC are slightly better than i...
Guardat en:
| Publicat a: | Visc Med |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6597907/ https://ncbi.nlm.nih.gov/pubmed/31312648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497464 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|